Abstract
The identification of 15N-labeled 3-nitrotyrosine (NTyr) by gas chromatography/mass spectroscopy in protein hydrolyzates from activated RAW 264.7 macrophages incubated with 15N-l-arginine confirms that nitric oxide synthase (NOS) is involved in the nitration of protein-bound tyrosine (Tyr). An assay is presented for NTyr that employs HPLC with tandem electrochemical and UV detection. The assay involves enzymatic hydrolysis of protein, acetylation, solvent extraction, O-deacetylation, and dithionite reduction to produce an analyte containing N-acetyl-3-aminotyrosine, an electrochemically active derivative of NTyr. We estimate the level of protein-bound NTyr in normal rat plasma to be ≈0–1 residues per 106 Tyr with a detection limit of 0.5 per 107 Tyr when ≥100 nmol of Tyr is analyzed and when precautions are taken to limit nitration artifacts. Zymosan-treated RAW 264.7 cells were shown to have an ≈6-fold higher level of protein-bound NTyr compared with control cells and cells treated with NG-monomethyl-l-arginine, an inhibitor of NOS. Intraperitoneal injection of F344 rats with zymosan led to a marked elevation in protein-bound NTyr to ≈13 residues per 106 Tyr, an ≈40-fold elevation compared with plasma protein of untreated rats; cotreatment with NG-monomethyl-l-arginine inhibited the formation of NTyr in plasma protein from blood and peritoneal exudate by 69% and 53%, respectively. This assay offers a highly sensitive and quantitative approach for investigating the role of reactive byproducts of nitric oxide in the many pathological conditions and disease states associated with NOx exposure such as inflammation and smoking.
Keywords: peroxynitrite, nitric oxide synthase, reactive nitrogen oxide species, zymosan
The proposed role for reactive nitrogen oxide species (NOx) in many pathological conditions related to human disease indicates a need for assays that detect the associated molecular modifications. One of these NOx species, peroxynitrite, which is generated in large part by the rapid reaction of endogenously formed nitric oxide (·NO) and superoxide (O2⨪) (1) is proposed, by virtue of its highly reactive nature, to play an important role in the host inflammatory response. Peroxynitrite damages protein (2), lipid (3), and DNA (4, 5) in vitro and may also mediate these potentially deleterious effects in various pathological conditions. This reactivity toward cellular constituents may be the basis by which overproduction of ·NO could exert cytotoxic effects (6). Other NOx and potent nitrating/nitrosating agents such as ·NO2 (7), NO2Cl (8), or N2O3 (9) may also be relevant in this regard. Previous work has demonstrated that the production of NOx in rodents assists the body’s defenses in killing foreign organisms that might otherwise continue to thrive at the host’s expense (10, 11). There also exist many pathological conditions, in which elevated NOS activity is implicated as a contributing factor to cellular injury, including chronic inflammation (12), heart ischemia-reperfusion injury (13, 14), and atherosclerosis (15).
3-Nitrotyrosine (NTyr) has been identified as a stable end product formed upon reaction of free or protein-bound Tyr with NOx such as peroxynitrite (7, 16), NO2· (7, 17, 18), NO2+ (19), HONO (19), and NO2Cl (8). Of these, peroxynitrite is postulated, based on its favorable reaction kinetics, to be the most relevant in regard to pathophysiological mechanisms related to many disease states. NTyr has been identified in biological samples using various detection techniques. Polyclonal and monoclonal antibodies raised against peroxynitrite-treated proteins have been used in numerous studies to identify NTyr in tissue sections (15, 20–22). Immunohistochemistry with these antibodies offers a powerful means of localizing NTyr within tissue but is regarded as less quantitative than chromatographic assays. Other quantitative approaches (19, 23–25) have not offered the sensitivity and convenience needed, thus prompting the current investigation.
MATERIALS AND METHODS
Materials.
Purchases were obtained as follows: NTyr, 3-aminotyrosine (ATyr), and tetranitromethane from Aldrich; sodium dithionite (DT; sodium hydrosulfite), HPLC-grade acetonitrile, and methanol from Fisher Scientific; [2,3,5,6-3H] l-tyrosine from Amersham; l-arginine·HCl (guanido-15N2, 98%+) from Cambridge Isotope Laboratories (Cambridge, MA); N-acetyl-l-tyrosine, l-tyrosine, triethylamine, and gas chromatography/mass spectroscopy (GC-MS) grade acetonitrile (>99%) from Fluka; N,O-bis(trimethylsilyl)trifluoroacetamide and trifluoroacetic acid from Pierce; NG-monomethyl-l-arginine (NMMA) from Cyclopss Biochem (Salt Lake City); DMEM from Irvine Scientific; undialyzed and dialyzed fetal bovine serum and zymosan A from Sigma; RPMI-SELECT-AMINE and murine recombinant interferon-γ (IFN-γ) from GIBCO/BRL; the transformed murine macrophage cell line RAW 264.7 from the American Type Culture Collection; Escherichia coli lipopolysaccharide serotype 055.B5 from Difco; potassium phosphate monobasic and dibasic, extra pure-grade sodium acetate trihydrate, GR-grade 90% formic acid, and phosphoric acid, OmniSolve-grade ethyl acetate, and Instrumental-grade/TRACEPUR HCl from Merck; sodium hydroxide and Baker reagent-grade 5 N volumetric solution from J. T. Baker; AR-grade acetic anhydride from Mallinckrodt; and pronase E from Boehringer Mannheim. MilliQ water free of nitrite and nitrate was used to prepare all buffers, mobile phases, and standard solutions.
Preparation of Standards.
The synthesis of 3H-NTyr was performed by mixing 50 μCi (1 Ci = 37 GBq) of high specific activity [2,3,5,6-3H]tyrosine (specific activity = 92 Ci/mmol), 2 μl of an ethanolic solution of tetranitromethane (840 mM), 20 μl H2O, and 2 μl 0.1 M Tris·HCl (pH 8). The mixture was allowed to react for 2 min and purified by HPLC to afford 3H-NTyr in 22% yield. N-acetyl-NTyr was prepared by acetylating NTyr with acetic anhydride as described below. The identities of the prepared compounds were verified by coelution with authentic standards, UV diode array and mass spectral, and DT-mediated conversion to ATyr. An N-acetyl 3-aminotyrosine (AcATyr) standard was prepared by DT-mediated reduction of N-acetyl-NTyr and stored without measurable decomposition for 6 months in 0.1 M HCl at −20°C.
Determination That the Nitro Group Is Derived from the Guanido Group of l-Arginine.
RAW 264.7 macrophages (3 × 108) were incubated in 10% dialyzed fetal bovine serum and amino acid defined RPMI (RPMI-SELECT-AMINE) reconstituted with all but 14N-l-arginine. The defined media was supplemented with 0.5 mM l-arginine·HCl (guanido-15N2) and allowed to exchange with 14N l-arginine pools for 24 h. The next day, medium was removed, the cells washed twice in PBS, and fresh media of the same composition used on the previous day was added along with lipopolysaccharide (100 ng·ml−1) and IFN-γ (10 units·ml−1). After 7 h, the medium was removed and replaced with Hanks’ buffer containing lipopolysaccharide, IFN-γ, phorbol myristate acetate (100 ng·ml−1), BSA (1 mg·ml−1), and 15N l-arginine (0.5 mM) and incubated for an additional 18 h. The culture was centrifuged at 300 × g for 5 min at 25°C. The supernatant was then filtered through a Centricon filtration device and the protein retentate washed with PBS to remove residual nitrite and nitrate. This protein was hydrolyzed with 6 M HCl for 24 h at 105°C. The sample was spiked with 3H-NTyr and fractionated by C18/OH solid phase extraction (Analytichem International, Harbor City, CA) using increasing amounts of methanol in 0.1 M trifluoroacetic acid to elute the NTyr. The 10% methanol/0.1 M trifluoroacetic acid fraction (42% recovery of 3H-Tyr) was concentrated to dryness and derivatized with 100 μl each of N,O-bis(trimethylsilyl)trifluoroacetamide and acetonitrile at 100°C for 1 h.
GC-MS Analysis.
Samples (1 μl) were delivered by splitless injection using a model 7673 automated liquid sampler linked to a Series II 5890 gas chromatograph/5989A mass spectrometer (Hewlett–Packard) with negative chemical ionization, an injection port temperature of 280°C, a purge activation time of 1 min, and a split vent flow of 50 ml−1·min−1. Ultra high purity methane (Matheson) was used as the carrier gas at a linear velocity of 55 cm−1·sec−1. Separations were achieved on a Hewlett–Packard Ultra-2 capillary column (12 m × 0.2 mm internal diameter × 0.33 μm film thickness) and the following temperature program: 50°C for 1 min followed by a 15°C per min linear ramp to 300°C with a 5-min hold. The GC-MS interface heater and source temperature was set to 300°C and 200°C, respectively.
Cell Culture.
RAW 264.7 macrophages were cultured at 37°C in 5% CO2 in DMEM supplemented with 10% fetal bovine serum. Cells (2 × 106 per well) were incubated in 24-well plates with various combinations of zymosan (0.5 mg·ml−1), IFN-γ (10 units·ml−1) and NMMA (1 mM) for a period of 24 h in a total volume of 2 ml. A portion of the spent media was used for nitrite determination by Griess reactivity and the remainder containing both medium and cells was used for NTyr determinations.
Zymosan Peritonitis.
All animal experimentation was performed under institutional approval. A stock solution of 50 mg·ml−1 zymosan prepared in sterile PBS was heat treated for 30 min at 95°C. Male Fischer 344 rats (180–220 gm) were injected with 250 mg·kg−1 of this suspension and killed after 72 h. Some rats also received either 300 or 150 mg·kg−1 dose of the NOS inhibitor NMMA immediately following injection with zymosan and further identical doses of this inhibitor on the second and third day. Rats were euthanized at 72 h with ether, and an axial incision was made to recover blood for plasma preparation (700 × g for 10 min). Sterile PBS (10 ml) with 20 units·ml−1 of sodium heparin was injected i.p. and the peritoneal cavity was massaged for 10 sec to distribute the PBS. The peritoneal exudate was removed with a syringe and transferred to a new Falcon polypropylene tube, which was subsequently centrifuged at 700 × g for 10 min at 4°C to pellet the peritoneal exudate cells. The cell-free peritoneal exudate was frozen at −80°C until used.
Preparation of Protein for Enzymatic Hydrolysis.
Protein suspensions were prepared in 0.1 M NaOAc buffer (pH 7.2) at an initial concentration of 3–5 mg protein per 0.5 ml. This suspension was precipitated with 0.8 ml HPLC grade acetonitrile, vortex mixed for 3 sec, and centrifuged at 700 × g for 10 min. The pellet was washed in 0.8 ml of NaOAc buffer, reprecipitated with 0.8 ml acetonitrile, vortex mixed, and centifuged, and the supernatant discarded as described above and washed once again. The sample was resuspended, sonicated (≈6-sec, 40-W burst) to produce a fine suspension of protein, precipitated once again, resuspended in 0.5 ml of 0.1 M NaOAc (pH 7.2), and sonicated once again. The extensive washing procedure was necessary to remove residual nitrite/nitrate and other contaminants. The sample was incubated overnight (12–16 h) at 50°C with 0.6 mg of dialyzed pronase E [≈20% (wt/wt) of the target protein]. Pronase E was prepared by dialysis (Spectra/Por 7; 15 kDa molecular cut-off; Spectrum Laboratories, Houston) against three daily changes of 0.1 M NaOAc (pH 7.2) (500 volume excess). The pronase contributed <2% of the Tyr recovered. The pelletable residue remaining after digestion of plasma protein was mostly nonproteinacious material and contained <2.5% of the total protein. Control experiments with nitrated bovine serum albumin indicated that the rates of enzymatic digestion for protein-bound NTyr and Tyr were essentially the same.
Derivatization and Extraction.
An equal volume (250 μl) of 3 M KH2PO4 (pH 9.6) was added to 50% of the sample followed by 20 μl acetic anhydride. After allowing the reaction to proceed for 10 min at 25°C, 1 ml of ethyl acetate was added followed by 135 μl of formic acid. The sample was vortex mixed for 10 sec and centrifuged at 700 × g for 1 min. The ethyl acetate phase was transferred to a 2 ml polypropylene microcentrifuge tube and concentrated to dryness under a gentle stream of N2 in a 50°C water bath.
Deacetylation and Dithionite Reduction.
Selective deacetylation of the phenolic acetate group of Tyr and NTyr was achieved by resuspending the sample in 175 μl of 0.3 M NaOH and allowing this mixture to react for 30 min at 37°C. After deacetylation, 175 μl of 1 M KH2PO4 (pH 6.5) buffer was added to adjust the pH to ≈7–7.5. The nitro substituent was reduced to the corresponding amine by adding 10 μl of 100 mM DT solution prepared in MilliQ water. After 10 min at 25°C, 35 μl of concentrated HCl was added to the sample. The samples were transferred to 30-kDa cutoff Millipore Ultrafree MC filters and centrifuged at 7,800 × g for 20 min. The filtrate was transferred to polypropylene autoinjector vials and analyzed.
HPLC-Electrochemical/UV Analysis.
Samples (100 μl) were delivered by an Hitachi AS4000 autosampler and chromatographed using a Waters model 625 solvent delivery system in combination with an Alltech Associates 5 μm C18 Alltima column (4.6 mm × 25 cm) equipped with a precolumn cartridge assembly at a flow rate of 1 ml·min−1. The gradient was as follows: 0–14 min 100% solvent A (1% methanol in 10 mM phosphoric acid, pH 2.56), 14–20 min linear ramp to 100% solvent B (50% methanol in 10 mM phosphoric acid), 20–35 min 100% solvent B, and 35–38 min linear ramp to 100% solvent A. Electrochemical (EC) detection of AcATyr utilized an ESA (Bedford, MA) model 5200 Coulochem detector and model 5011 analytical cell with potentials of electrodes 1 and 2 adjusted to 0.00 and 0.07 V, respectively. N-acetyltyrosine (AcTyr) was detected at 280 nm (model 773; Kratos Analytical Instruments). AcATyr and AcTyr elute at ≈11.5 and 23.5 min. Mole quantities were determined against authentic calibrated standards. The calculated mole ratio values AcATyr per 106 AcTyr and NTyr per 106 Tyr are treated as equivalent expressions.
RESULTS
Incorporation of 15N-Labeled Guanido Nitrogen Atom of l-Arginine into NTyr: Detection of Protein-Bound 3-(15NO2)-Tyrosine.
Macrophage NOS catalyzes the NADPH-dependent oxidation of l-arginine to l-citrulline and ·NO (26), the latter of which can subsequently be transformed to NOx. To establish l-arginine as the source of the nitro substituent nitrogen atom in NTyr, l-arginine (guanido-15N2) was used as the substrate for the inducible NOS present in RAW 264.7 macrophages.
Table 1 shows the major ions obtained from the negative chemical ionization of the tri-trimethylsilyl (TMS) derivative of authentic NTyr and putative NTyr isolated from protein hydrolyzates of RAW 264.7 macrophages activated with lipopolysaccharide, IFN-γ, and phorbol myristate acetate in the presence of l-arginine·HCl (guanido-15N2). Ionization of authentic tri-TMS-NTyr (M = m/z 441) results in the loss of one O-TMS group producing the characteristic ion at m/z 352 [M − C3H9OSi]− or both O-TMS groups and decarboxylation to yield the ion m/z 236 [M − C7H18O3Si2]−. By comparing the relative abundances of the major ions obtained from analysis of the sample incubated with 15N-l-arginine to that of authentic NTyr (Table 1), we observe a marked shift in ion abundance from m/z 352 and m/z 236 to m/z 353 and m/z 237, respectively. This indicates that one of the guanido nitrogens of l-arginine is the source of the nitro group nitrogen atom of NTyr, thereby confirming the role of NOS in the formation of NTyr.
Table 1.
m/z | Authentic NTyr | NTyr from 15N-l-Arg + Macrophage |
---|---|---|
236 | 91.4 ± 14.1 | 21.5 ± 0.4 |
237 | 16.9 ± 2.6 | 89.3 ± 3.9 |
238 | 5.3 ± 0.9 | 16.5 ± 1.0 |
352 | 100.0 ± 16.3 | 18.1 ± 4.6 |
353 | 28.1 ± 4.8 | 100.0 ± 10.4 |
354 | 11.9 ± 2.3 | 75.2 ± 5.2 |
Relative ion intensities of the major fragments, m/z 236–238 [M − C7H18O3Si2]− and m/z 352–354 [M − C3H9OSi]− derived from the corresponding tri-trimethylsilyl derivatives. Values represent the mean ± SD of three determinations.
Electrochemical Detection of AcATyr.
Our attempts to apply mass spectral analysis to the quantitation of NTyr met with difficulty though recent efforts by others have proved successful (see note added in proof). We therefore measured NTyr by HPLC with EC detection, a method with sensitivity comparable to GC-MS with negative chemical ionization (≈20 vs. 5 fmol on-column detection limit, respectively) and ≈103 fold higher than that of UV detection. EC detection of NTyr required +0.88 V for maximal response, making it difficult to selectively detect this modified amino acid among other components present in protein hydrolyzates from activated macrophage incubates. This led to the development of a method involving the DT-mediated conversion of NTyr to ATyr (27), an EC active compound with a low oxidation potential. The poor retention of ATyr on a C18 reversed phase column, however, prompted the development of a derivatization and extraction scheme that enriches for hydrophobic amino acids and improves the chromatography. The method for measuring NTyr (Fig. 1) involves enzymatic hydrolysis of protein, acetylation, extraction, O-deacetylation, and chemical reduction with DT to produce AcATyr. AcATyr has a half potential of +0.037 V with >90% oxidation at 0.070 V. The recovery of NTyr as AcATyr in rat plasma was determined across a broad range of NTyr (225 fmol to 22.5 pmol) that had been spiked into this biological matrix prior to enzymatic digestion and processing. The recovery was estimated to be ≈70–75% with good linearity (r2 = 0.9995). Tyr was shown to be recovered with similar efficiency, thus no correction for recoveries are made in expressing the mole ratios of AcATyr to AcTyr. Enzymatic hydrolysis of tetranitromethane-treated BSA resulted in >95% release of both NTyr and Tyr.
Acid Artifacts and Nitrotyrosine.
Numerous examples exist for acid-catalyzed nitration of phenolics (28) such as Tyr (19), in the presence of nitrites or nitrates. AcTyr, in the presence of physiological concentrations (10 μM) of nitrite or nitrate under acidic conditions (1 M HCl), forms significant amounts of N-acetyl-NTyr, indicating that ex vivo nitrosation/nitration of Tyr can result in levels of NTyr that may obscure those formed in vivo (Table 2). Addition of 1% phenol to AcTyr samples containing 10 μM sodium nitrate inhibited artifact formation effectively (≈63%), though not completely as did other phenolic compounds and ammonium sulfamate (data not shown).
Table 2.
AcATyr per 106 AcTyr | |
---|---|
AcTyr | 0.4 ± 0.1 |
+ HCl | 2.0 ± 0.3† |
+ HCl + NaNO2* | 98.7 ± 10.0‡ |
+ HCl + NaNO3 | 10.3 ± 7.0§ |
+ HCl + NaNO3 + 1% phenol | 3.8 ± 2.3§ |
AcTyr (1 mM) was incubated in 0.1 M NaOAc (pH 7.2) for 30 min on ice. Where indicated, 1 M HCl, sodium nitrite (10 μM), or sodium nitrate (10 μM), and/or 1% phenol were also included in the incubate. Samples were concentrated to dryness, reconstituted in 0.5 M KH2PO4 buffer (pH 7.0), reduced with DT, and analyzed as described.
Control experiments indicated that N-acetyl-NTyr was the exclusive product of this nitrosation reaction. Values represent the mean ± SD of three determinations.
P < 0.0005;
P < 0.0001;
P < 0.05 compared to AcTyr control; one-tailed Students t test.
Peroxynitrite-Mediated Nitration of Rat Plasma Protein.
The rigorous control of residual nitrite and nitrate allowed us to examine the nitrating potential of peroxynitrite in a biological matrix. Rat plasma was treated with peroxynitrite and the amount of NTyr (as AcATyr) measured (Fig. 2.). Incremental increases in NTyr were observed with as little as 10 μM peroxynitrite (P < 0.05, one-tailed Student’s t test), despite the presence of 23 μM ascorbate and other plasma antioxidants that were not monitored. The NTyr levels correlated well with the amount of peroxynitrite added to the samples. A marked rise in NTyr formation was observed with the addition of 1 mM peroxynitrite, presumably reflecting consumption of key plasma antioxidants that, in turn, allows for greater nitration efficiency. The addition of 10 mM decomposed peroxynitrite, however, produced NTyr values that were comparable to untreated plasma samples, thus indicating the specificity of peroxynitrite to the NTyr measured, and the rigor of the removal of contaminating traces of nitrite and nitrate. When rat plasma was spiked with 10 μM sodium nitrite and 100 μM sodium nitrate prior to sample processing, no significant elevation in NTyr was observed as the AcATyr per 106 AcTyr ratio of spiked samples (0.05 ± 0.07) versus unspiked samples (0.04 ± 0.04; both sets expressed as mean ± SD, n = 4) were comparable. These results again confirm the efficient removal of nitrite and nitrate from the sample. Comparable baseline values (0–1 AcATyr per 106 AcTyr) are observed with human plasma samples from healthy individuals (data not shown).
Zymosan-Activated RAW 264.7 Macrophage and Protein Nitration.
The activation of RAW 264.7 macrophages with zymosan alone resulted in 5 NTyr per 106 Tyr, which increased further to ≈7 per 106 Tyr when IFN-γ was also present (Table 3, Fig. 3.). Treatment of RAW cells with IFN-γ alone had no significant effect. The marked elevation in NTyr observed with the combination of zymosan and IFN-γ was blocked almost completely with 1 mM NMMA. Nitrite and NTyr levels correlated well.
Table 3.
AcATyr per 106 AcTyr | Nitrite, μM | |
---|---|---|
Untreated | 1.05 ± 0.46 | 4.6 ± 1.0 |
Zymosan | 5.13 ± 0.57* | 53.5 ± 1.2 |
IFN-γ | 1.30 ± 0.49 | 11.1 ± 2.9 |
Zymosan + IFN-γ | 7.52 ± 0.13*† | 71.0 ± 3.7 |
Zymosan + IFN-γ + NMMA | 1.30 ± 0.43 | 12.4 ± 0.4 |
Values are expressed as mean ± SD (n = 4 determinations for all conditions).
P < 0.01 vs. untreated control;
P < 0.001 (zymosan + IFN-γ vs. Zymosan); P values calculated by one-way ANOVA, Bonferroni multiple comparison test.
Zymosan Peritonitis and Protein Nitration.
F344 rats injected i.p. with a single 250 mg·kg−1 dose of zymosan exhibited overt signs of systemic illness within the first 2–4 h after injection. Approximately 20% of the zymosan-treated rats died within the first 24–36 h while the surviving animals showed marked weight loss (10–15%) over the first 72-h period after injection. Leakage of plasma protein into the peritoneal cavity was noted in all zymosan-treated animals.
Plasma protein isolated from either blood or peritoneal exudate revealed markedly higher levels of NTyr compared with blood plasma of PBS-treated animals (Table 4). Treatment of rats with zymosan and NMMA was complicated by their low tolerance to this combination of agents at the doses used. Initially, injection of 300 mg·kg−1 of NMMA to the zymosan-treated rats resulted in the loss of seven of the eight animals treated, suggesting a possible protective effect or important regulatory role of ·NO in inflammatory injury. Lowering the dose to 150 mg·kg−1 increased the survival to two out of a total of five animals. From these three surviving animals, 69% and 53% reduction in plasma protein NTyr was observed from blood and exudate, respectively, compared to zymosan treatment only, thus demonstrating in vivo a relationship between NTyr formation and NOS activity. The marked reduction in NTyr, however, did not correlate with improved vitality. Animals treated with the combination of zymosan and NMMA lost weight, exhibited comparable amounts of plasma protein in the peritoneal cavity, and showed signs of morbidity similar to that of the rats treated with zymosan only.
Table 4.
n | AcATyr per 106 AcTyr
|
||
---|---|---|---|
Plasma | Exudate | ||
PBS | 6 | 0.37 ± 0.32 | ND |
Zymosan | 5 | 12.46 ± 3.13* | 14.11 ± 2.33* |
Zymosan + NMMA | 3 | 3.82 ± 2.88† | 6.69 ± 1.48‡ |
Values are given as mean ± SD. ND, not determined.
P < 0.001 vs. PBS-plasma;
P < 0.001 vs. zymosan;
P < 0.01 vs. zymosan-exudate; P values calculated by one-way ANOVA, Bonferonni multiple comparison test.
DISCUSSION
Evidence implicating NOx in inflammation, cancer, and many of the degenerative diseases of aging has prompted an assessment of the role of NOS in tyrosine nitration and the development of a sensitive and selective HPLC-EC assay to quantitate NTyr as AcATyr. This assay for NTyr complements the widely used immunohistochemical assay and quantitates the NOS-dependent formation of this molecular lesion in a variety of sample types, thereby potentially extending the range of experiments designed to examine the relationship between ·NO production and the many pathological conditions associated with this enzyme activity.
Rigorous control of residual nitrite and nitrate and the use of mild nonacidic enzymatic hydrolysis reduced the baseline (≤1 NTyr per 106 Tyr) to levels considerably lower than those previously reported (23, 25, 29, 30) and increased the effective sensitivity of NTyr determination from biological samples. Artifactual levels of NTyr (101–104 NTyr per 106 Tyr) were seen without this rigorous cleanup.
The yeast cell wall component zymosan is a potent activator of phagocytic cells and has been used in the current study to validate the NTyr assay in vitro and in vivo. Zymosan- and IFN-γ-treated RAW 264.7 macrophages produce marked increases in NTyr, possibly reflecting the formation of the same NOx that are responsible for the killing of foreign organisms. Murine peritoneal macrophages, for example, kill Leishmania major when challenged with zymosan and IFN-γ, an effect that is inhibited by addition of the NOS inhibitor, N-iminoethyl-l-ornithine (31). Thus, production of NOx, that include such potent oxidants and nitrating agents as peroxynitrite or N2O3, could in large part be responsible for this cytotoxic effect.
The marked elevation in NTyr found with zymosan-treated RAW 264.7 or in zymosan-induced peritonitis illustrates a vigorous response by the host inflammatory machinery to an agent that it recognizes as foreign. This response is important in the host’s resistance to the invading pathogen, but can also damage host tissue. For example, zymosan-induced peritonitis, an acute non-pathogen-induced inflammation is characterized by extravasation of plasma protein and infiltration of activated neutrophils and macrophages into the peritoneal cavity. This model of sterile peritonitis exhibits many features of the host response to microbial invasion of tissues, including high output phagocyte-derived synthesis of ·NO, oxidant production and damage, glutathione depletion, hypotension, and distant organ failure (32, 33). When this host inflammatory response is drawn out under chronic conditions (i.e., hepatitis, idiopathic bowel disease), elevated ·NO production is also likely to participate in the process leading to cellular injury. The identification of NTyr can provide the necessary evidence to link NOS activity to these chronic diseases.
The low levels of NTyr detected in treated animals suggests that Tyr may not be a preferred target of NOx. Monitoring Tyr nitration, however, can provide evidence for the existence of endogenously produced NOx. Measuring the nitration of other phenolic species within the body could serve a similar function. Dietary nucleophilic phenolic compounds such as γ-tocopherol (34) has been shown to be a defense “trap” for NOx, and the many polyphenolic compounds in our diet (flavonoids, tea, and wine polyphenolics), may also compete effectively with Tyr for the endogenous NOx generated during inflammation (35). The reported anti-inflammatory action of these chemicals, may, in part, be rooted in their ability to efficiently trap these species.
We have described in the current study that zymosan and cytokine activated murine macrophages produce NOx capable of nitrating tyrosine residues in protein. Other cells, including those with macrophage-like function (e.g., including Kupffer cells, alveolar macrophages, microglia, Langerhans cells, and retinal pigment epithelial cells), can also be triggered by cytokines to produce elevated levels of ·NO that may also be accompanied by increased synthesis of NOx such as peroxynitrite. The increased output of NOx by these cells may contribute to increased resistance to various pathogens as well as susceptibility to cell injury that can occur during acute and chronic inflammatory conditions. The assay for NTyr could assist in delineating the role of macrophage-derived NOx in these processes, and serve as a biomarker in animal models and human populations to determine the efficacy of nutritional or pharmacological interventions.
Acknowledgments
We thank J. Eiserich, A. Glazer, J. Hibbs, and A. van der Vliet for suggestions and critical reading of this manuscript; T. Hagen, C. Wehr, and J. Lykkesfeldt for help with animals; C. Grunfeld (San Francisco Veterans Administration Medical Center) for the RAW 264.7 macrophages; and A. Fisher for maintaining these cultures. This work was supported by National Cancer Institute Outstanding Investigator Grant CA 39910 and National Institute of Environmental Health Sciences Center Grant ES 01896 (B.N.A.).
ABBREVIATIONS
- AcATyr
N-acetyl 3-aminotyrosine
- AcTyr
N-acetyltyrosine
- ATyr
3-aminotyrosine
- DT
sodium dithionite
- EC
electrochemical
- IFN-γ
interferon γ
- NMMA
NG-monomethyl-l-arginine
- NOS
nitric oxide synthase
- NOx
reactive nitrogen oxide species
- NTyr
3-nitrotyrosine
- GC-MS
gas chromatography/mass spectroscopy
Note Added in Proof
The successful application of GC-MS in the analysis of NTyr from low density lipoprotein isolated from human atherosclerotic tissue has recently been described (36).
References
- 1.Huie R E, Padmaja S. Free Radical Res Commun. 1993;18:195–199. doi: 10.3109/10715769309145868. [DOI] [PubMed] [Google Scholar]
- 2.Ischiropoulos H, Zhu L, Beckman J S. Arch Biochem Biophys. 1992;298:446–451. doi: 10.1016/0003-9861(92)90433-w. [DOI] [PubMed] [Google Scholar]
- 3.Radi R, Beckman J S, Bush K M, Freeman B A. Arch Biochem Biophys. 1991;288:481–487. doi: 10.1016/0003-9861(91)90224-7. [DOI] [PubMed] [Google Scholar]
- 4.Douki T, Cadet J, Ames B N. Chem Res Toxicol. 1996;9:3–7. doi: 10.1021/tx950126n. [DOI] [PubMed] [Google Scholar]
- 5.Yermilov V, Rubio J, Becchi M, Friesen M D, Pignatelli B, Ohshima H. Carcinogenesis. 1995;16:2045–2050. doi: 10.1093/carcin/16.9.2045. [DOI] [PubMed] [Google Scholar]
- 6.Beckman J S, Beckman T W, Chen J, Marshall P A, Freeman B A. Proc Natl Acad Sci USA. 1990;87:1620–1624. doi: 10.1073/pnas.87.4.1620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.van der Vliet A, Eiserich J P, O’Neill C A, Halliwell B, Cross C E. Arch Biochem Biophys. 1995;319:341–349. doi: 10.1006/abbi.1995.1303. [DOI] [PubMed] [Google Scholar]
- 8.Eiserich J P, Cross C E, Jones A D, Halliwell B, van der Vliet A. J Biol Chem. 1996;271:19199–19208. doi: 10.1074/jbc.271.32.19199. [DOI] [PubMed] [Google Scholar]
- 9.Kharitonov V G, Sundquist A R, Sharma V S. J Biol Chem. 1995;270:28158–28164. doi: 10.1074/jbc.270.47.28158. [DOI] [PubMed] [Google Scholar]
- 10.Nathan C F, Hibbs J B., Jr Curr Opin Immunol. 1991;3:65–70. doi: 10.1016/0952-7915(91)90079-g. [DOI] [PubMed] [Google Scholar]
- 11.Hibbs J B, Jr, Vavrin Z, Taintor R R. J Immunol. 1987;138:550–565. [PubMed] [Google Scholar]
- 12.Liu R H, Hotchkiss J H. Mutat Res. 1995;339:73–89. doi: 10.1016/0165-1110(95)90004-7. [DOI] [PubMed] [Google Scholar]
- 13.Matheis G, Sherman M P, Buckberg G D, Haybron D M, Young H H, Ignarro L J. Am J Physiol. 1992;262:H616–H620. doi: 10.1152/ajpheart.1992.262.2.H616. [DOI] [PubMed] [Google Scholar]
- 14.Patel V C, Yellon D M, Singh K J, Neild G H, Woolfson R G. Biochem Biophys Res Commun. 1993;194:234–238. doi: 10.1006/bbrc.1993.1809. [DOI] [PubMed] [Google Scholar]
- 15.Beckmann J S, Ye Y Z, Anderson P G, Chen J, Accavitti M A, Tarpey M M, White C R. Biol Chem Hoppe-Seyler. 1994;375:81–88. doi: 10.1515/bchm3.1994.375.2.81. [DOI] [PubMed] [Google Scholar]
- 16.Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin J C, Smith C D, Beckman J S. Arch Biochem Biophys. 1992;298:431–437. doi: 10.1016/0003-9861(92)90431-u. [DOI] [PubMed] [Google Scholar]
- 17.Prutz W A, Monig H, Butler J, Land E J. Arch Biochem Biophys. 1985;243:125–134. doi: 10.1016/0003-9861(85)90780-5. [DOI] [PubMed] [Google Scholar]
- 18.Kikugawa K, Kato T, Okamoto Y. Free Radical Biol Med. 1994;16:373–382. doi: 10.1016/0891-5849(94)90039-6. [DOI] [PubMed] [Google Scholar]
- 19.Ohshima H, Friesen M, Brouet I, Bartsch H. Food Chem Toxicol. 1990;28:647–652. doi: 10.1016/0278-6915(90)90173-k. [DOI] [PubMed] [Google Scholar]
- 20.Miller M J, Thompson J H, Zhang X J, Sadowska-Krowicka H, Kakkis J L, Munshi U K, Sandoval M, Rossi J L, Eloby-Childress S, Beckman J S, Ye Y Z, Rodi C P, Manning P T, Currie M G, Clark D A. Gastroenterology. 1995;109:1475–1483. doi: 10.1016/0016-5085(95)90633-9. [DOI] [PubMed] [Google Scholar]
- 21.Kooy N W, Royall J A, Ye Y Z, Kelly D R, Beckman J S. Am J Respir Crit Care Med. 1995;151:1250–1254. doi: 10.1164/ajrccm/151.4.1250. [DOI] [PubMed] [Google Scholar]
- 22.Ischiropoulos H, Beers M F, Ohnishi S T, Fisher D, Garner S E, Thom S R. J Clin Invest. 1996;97:2260–2267. doi: 10.1172/JCI118667. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kaur H, Halliwell B. FEBS Lett. 1994;350:9–12. doi: 10.1016/0014-5793(94)00722-5. [DOI] [PubMed] [Google Scholar]
- 24.Haddad, I. Y., Ischiropoulos, H., Holm, B. A., Beckman, J. S., Baker, J. R. & Matalon, S. (1993) Am. J. Physiol. L555–L564. [DOI] [PubMed]
- 25.Schulz J B, Matthews R T, Muqit M M, Browne S E, Beal M F. J Neurochem. 1995;64:936–939. doi: 10.1046/j.1471-4159.1995.64020936.x. [DOI] [PubMed] [Google Scholar]
- 26.Marletta M A, Yoon P S, Iyengar R, Leaf C D, Wishnok J S. Biochemistry. 1988;27:8706–8711. doi: 10.1021/bi00424a003. [DOI] [PubMed] [Google Scholar]
- 27.Sokolovsky M, Riordan J F, Vallee B L. Biochem Biophys Res Commun. 1967;27:20–25. doi: 10.1016/s0006-291x(67)80033-0. [DOI] [PubMed] [Google Scholar]
- 28.Olah G A, Malhotra R, Narang S C. Nitration: Methods and Mechanisms. New York: VCH; 1989. [Google Scholar]
- 29.Ischiropoulos H, al-Mehdi A B, Fisher A B. Am J Physiol. 1995;269:L158–L164. doi: 10.1152/ajplung.1995.269.2.L158. [DOI] [PubMed] [Google Scholar]
- 30.Salman-Tabcheh S, Guerin M C, Torreilles J. Free Radical Biol Med. 1995;19:695–698. doi: 10.1016/0891-5849(95)00075-9. [DOI] [PubMed] [Google Scholar]
- 31.Assreuy J, Cunha F Q, Epperlein M, Noronha-Dutra A, O’Donnell C A, Liew F Y, Moncada S. Eur J Immunol. 1994;24:672–676. doi: 10.1002/eji.1830240328. [DOI] [PubMed] [Google Scholar]
- 32.Demling R, Lalonde C, Youn Y K, Daryani R, Campbell C, Knox J. Am Rev Respir Dis. 1992;146:1272–1278. doi: 10.1164/ajrccm/146.5_Pt_1.1272. [DOI] [PubMed] [Google Scholar]
- 33.Boughton-Smith, N. K. & Ghelani, A. (1995) Inflammation Res. 44, Suppl 2, S149–S150. [DOI] [PubMed]
- 34.Christen S, Woodall A A, Shigenaga M K, Southwell-Keely P T, Duncan M W, Ames B N. Proc Natl Acad Sci USA. 1997;94:3217–3222. doi: 10.1073/pnas.94.7.3217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Fiala E S, Sodum R S, Bhattacharya M, Li H. Experientia. 1996;52:922–926. doi: 10.1007/BF01938881. [DOI] [PubMed] [Google Scholar]
- 36.Leeuwenburgh C, Hardy M M, Hazen S L, Wagner P, Oh-ishi S, Steinbrecher U P, Heinecke J W. Biol Chem. 1997;272:1433–1436. doi: 10.1074/jbc.272.3.1433. [DOI] [PubMed] [Google Scholar]